Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2019-12-16
Target enrollment:
Participant gender:
Summary
Type 2 diabetes (T2DM) is related to reduced pulmonary function. As experimental studies with
glucagon-like peptide 1 (GLP-1) have shown an increase in pulmonary surfactant secretion, and
the GLP-1 receptor has been found in significant amounts in the lung, it could be
hypothesized that the treatment with liraglutide (a GL-1 agonist) will improve this reduced
pulmonary function